[Role of the combination of trastuzumab and taxanes in the therapeutic management of cancer of the breast: from preclinical data to clinical application]

Mario Campone; Jean-Louis Merlin; Pierre Fumoleau

[Role of the combination of trastuzumab and taxanes in the therapeutic management of cancer of the breast: from preclinical data to clinical application]

Bull Cancer. 2003 Jul;90(7):614-22.

[Article in French]

Authors

Mario Campone¹, Jean-Louis Merlin, Pierre Fumoleau

Affiliation

¹ Centre René-Gauducheau, boulevard Jacques-Monod, 44805 Saint-Herblain, France. [email protected]

PMID: 12957803

Abstract

Taxanes are major drugs in the treatment of breast metastatic cancer. Since 1990, the mechanisms implicated in carcinogenesis are better understood and the oncoprotein HER2 is a potential target. Trastuzumab is a monoclonal antibody that binds to this transmembrane glycoprotein. This antibody demonstrated a significant activity in clinical trials. In this review, we discuss the preclinical (mechanisms of action) and clinical data with the combination of trastuzumab and taxanes.

Publication types

Review

MeSH terms

Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Breast Neoplasms / drug therapy*
Breast Neoplasms / genetics
Cisplatin / administration & dosage
Docetaxel
Drug Screening Assays, Antitumor
Female
Humans
Neoadjuvant Therapy
Paclitaxel / administration & dosage
Paclitaxel / analogs & derivatives*
Prospective Studies
Randomized Controlled Trials as Topic
Receptor, ErbB-2 / physiology*
Taxoids*
Trastuzumab

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Taxoids
Docetaxel
Receptor, ErbB-2
Trastuzumab
Paclitaxel
Cisplatin